Lower-Risk MDS: A Review of Data from the ASH 2022 Annual Meeting : Episode 1

First- and Second-Line Treatment Options in Lower-Risk MDS

Feb 24, 2023

Rami Komrokji, MD
Amer Zeidan, MBBS, MHS

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

EP: 1.First- and Second-Line Treatment Options in Lower-Risk MDS

EP: 2.Luspatercept in Lower-Risk MDS

EP: 3.Emerging Therapies for Lower-Risk MDS

Related Videos

Jorge E. Cortes, MD

Julie Renee Brahmer, MD

Bradley W. Christensen, MD

Anne Chiang, MD, PhD, associate professor, medical oncology, Yale School of Medicine, associate cancer center director, Clinical Initiatives, Smilow Cancer Hospital, Yale Cancer Center

Expert on CSCC

Expert on CSCC

Experts on BTC

Experts on BTC

Aaron Gerds, MD, an expert on myeloproliferative neoplasms

Expert on AML

Related Content

Emerging Data Offer Alternatives for Patients With Lower-Risk MDS

March 23rd 2023

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

Integrating New Standards for Metastatic HER2+ Breast Cancer

March 20th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors

March 17th 2023

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Emerging Data Offer Alternatives for Patients With Lower-Risk MDS

March 23rd 2023

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

Integrating New Standards for Metastatic HER2+ Breast Cancer

March 20th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors

March 17th 2023

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Emerging Data Offer Alternatives for Patients With Lower-Risk MDS

March 23rd 2023

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

Integrating New Standards for Metastatic HER2+ Breast Cancer

March 20th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors

March 17th 2023

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Related Content

Rami Komrokji, MD

Emerging Data Offer Alternatives for Patients With Lower-Risk MDS

March 23rd 2023

Roy S. Herbst, MD, PhD

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

Debu Tripathy, MD

Integrating New Standards for Metastatic HER2+ Breast Cancer

March 20th 2023

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Timothy Yap, MBBS, PhD, FRCP

PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors

March 17th 2023

Mayur Narkhede, MD

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Latest Conference Coverage

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.